Linzagolix


Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2017, it is in phase III clinical trials for uterine fibroids and phase II clinical studies for endometriosis and adenomyosis.